Full Text Available

Note: Clicking the button above will open the full text document at the original institutional repository in a new window.

The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population

Background: Warfarin is the most commonly used drug in the management of thromboembolic disease. However, there is a huge variability in the management of warfarin affecting the international normalized ratio (INR). Many genetic-association studies have reported on European and Asian populations whi...

Full description

Saved in:
Bibliographic Details
Main Author: Cindi, Zinhle
Other Authors: Dandara, Collet
Format: Thesis
Language:English
Published: Department of Pathology 2019
Subjects:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867613222445514752
access_status_str Open Access
author Cindi, Zinhle
author2 Dandara, Collet
author_browse Cindi, Zinhle
Dandara, Collet
author_facet Dandara, Collet
Cindi, Zinhle
author_sort Cindi, Zinhle
collection Thesis
description Background: Warfarin is the most commonly used drug in the management of thromboembolic disease. However, there is a huge variability in the management of warfarin affecting the international normalized ratio (INR). Many genetic-association studies have reported on European and Asian populations which has led to the designing of specific algorithms that are now being used to assist in warfarin dosing. However, very few or no studies have looked at the pharmacogenetics of warfarin in African populations, yet, huge differences in dosage requirements to reach the same INR have been observed. We set out to investigate genetic factors affecting warfarin therapy in South African black (SAB) and Mixed Ancestry (MA) participants. Methods: We recruited consenting participants from Groote Schuur Hospital and Gugulethu Community Health Centre comprising 263 of Mixed Ancestry (MA) descent and 109 of South African black (SAB) descent. Demographic data, clinical information and 5 ml of blood for genetic characterization was obtained from participants. DNA was extracted from the blood and genotyped using PCR/RFLP and Sanger sequencing for 5 single nucleotide polymorphisms (SNPs), VKORC1 c.-1639G>A, VKORC1 c.1173C>T, VKORC1 c.3730G>A, GGCX c.1218C>T and GGCX c.1242C>T. Results: We report an association of age with warfarin dose, where, older patients had lower dose requirements (p>0.001 in MA; p>0.042 in SAB). Higher BMI was associated with increased stabilizing dose in the MA group (p=0.003). The SNP VKORC1 c.-1639G>A was associated with stabilizing dose only in MA (p>0.003), with carriers of the A/A genotype requiring lower dosages (18 ± 14 mg/week) compared to G/G (38 ± 14 mg/week). Conclusion: We conclude that environmental and genetic factors may play a role in the way South African patients respond to warfarin. Particularly, it appears as if MA and SAB population group have different underlying genetic markers for warfarin response. This knowledge in warfarin pharmacogenomics could help in the judicious use of warfarin in South African patients. However, more genetic markers need to be characterized to understand the profiles of genetic determinants affecting responses to warfarin therapy in world populations.
format Thesis
id oai:open.uct.ac.za:11427/29461
institution University of Cape Town (South Africa)
language eng
last_indexed 2026-06-10T12:32:42.829Z
license_str Not specified — see source repository
provenance_str_mv Harvested via OAI-PMH from UCTD — University of Cape Town Open Access Repository
publishDate 2019
publishDateRange 2019
publishDateSort 2019
publisher Department of Pathology
publisherStr Department of Pathology
record_format dspace
source_str UCTD — University of Cape Town Open Access Repository
spelling oai:open.uct.ac.za:11427/29461 The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population Cindi, Zinhle Dandara, Collet Ntsekhe, Mpiko Mpye, Keleabetswe Medicine Background: Warfarin is the most commonly used drug in the management of thromboembolic disease. However, there is a huge variability in the management of warfarin affecting the international normalized ratio (INR). Many genetic-association studies have reported on European and Asian populations which has led to the designing of specific algorithms that are now being used to assist in warfarin dosing. However, very few or no studies have looked at the pharmacogenetics of warfarin in African populations, yet, huge differences in dosage requirements to reach the same INR have been observed. We set out to investigate genetic factors affecting warfarin therapy in South African black (SAB) and Mixed Ancestry (MA) participants. Methods: We recruited consenting participants from Groote Schuur Hospital and Gugulethu Community Health Centre comprising 263 of Mixed Ancestry (MA) descent and 109 of South African black (SAB) descent. Demographic data, clinical information and 5 ml of blood for genetic characterization was obtained from participants. DNA was extracted from the blood and genotyped using PCR/RFLP and Sanger sequencing for 5 single nucleotide polymorphisms (SNPs), VKORC1 c.-1639G>A, VKORC1 c.1173C>T, VKORC1 c.3730G>A, GGCX c.1218C>T and GGCX c.1242C>T. Results: We report an association of age with warfarin dose, where, older patients had lower dose requirements (p>0.001 in MA; p>0.042 in SAB). Higher BMI was associated with increased stabilizing dose in the MA group (p=0.003). The SNP VKORC1 c.-1639G>A was associated with stabilizing dose only in MA (p>0.003), with carriers of the A/A genotype requiring lower dosages (18 ± 14 mg/week) compared to G/G (38 ± 14 mg/week). Conclusion: We conclude that environmental and genetic factors may play a role in the way South African patients respond to warfarin. Particularly, it appears as if MA and SAB population group have different underlying genetic markers for warfarin response. This knowledge in warfarin pharmacogenomics could help in the judicious use of warfarin in South African patients. However, more genetic markers need to be characterized to understand the profiles of genetic determinants affecting responses to warfarin therapy in world populations. 2019-02-11T12:44:10Z 2019-02-11T12:44:10Z 2018 2019-02-11T12:43:15Z Master Thesis Masters MSc http://hdl.handle.net/11427/29461 eng application/pdf Department of Pathology Faculty of Health Sciences University of Cape Town
spellingShingle Medicine
Cindi, Zinhle
The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
thesis_degree_str Master's
title The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
title_full The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
title_fullStr The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
title_full_unstemmed The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
title_short The role of genetic variation in VKORC1 and GGCX on warfarin response in a South African population
title_sort role of genetic variation in vkorc1 and ggcx on warfarin response in a south african population
topic Medicine
url http://hdl.handle.net/11427/29461
work_keys_str_mv AT cindizinhle theroleofgeneticvariationinvkorc1andggcxonwarfarinresponseinasouthafricanpopulation
AT cindizinhle roleofgeneticvariationinvkorc1andggcxonwarfarinresponseinasouthafricanpopulation